The data will be presented at a urology meeting this month.

Released by Lumenis two years ago, MOSES Technology is a revolutionary, patent-protected technology that optimizes holmium energy transmission using a unique pulse modulation. Significant clinical evidence highlighting the benefits of MOSES in lithotripsy has demonstrated a 20% reduction in procedure time, 25% improvement in fragmentation efficiency and 60% reduction in stone retropulsion.

For BPH, MOSES Technology has recently been added to Holmium Laser Enucleation of the Prostate (HoLEP), a procedure long recognized as the gold standard treatment for any prostate size, with exceptional long-term durability compared to other minimally invasive options. With the addition of MOSES to HoLEP, this superior treatment technique has already demonstrated advantages of shorter procedure time, better hemostasis6,7 and improved tissue separation8 – all of which could potentially shorten the physician learning curve and enable better patient care.

“I have been researching MOSES for BPH and I have found significant improvement in procedure time and hemostasis time,” said Dr. Amy E. Krambeck, Professor of Urology at Indiana University. “This clear, measurable clinical value translated into treating more patients each day in my practice and the team and I are grateful for that. With this new technology we have been successful in transitioning the majority of our HoLEP procedures to same day discharge home. I look forward to publishing these results soon.”

The advantages of MOSES for lithotripsy and BPH procedures are continuously researched and demonstrated by leading academic institutions worldwide. At the American Urological Association’s (AUA) annual meeting, taking place in Chicago, May 3-6, 2019, new clinical data will be presented demonstrating advantages in BPH procedures, particularly in MOSES for HoLEP (MoLEP).

In addition to MOSES taking center stage during the AUA, Lumenis will host educational activities including the Laser Lithotripsy Around the World Panel with Dr. Oriol Angerri, Prof. Thomas Knoll and Dr. Richard Batstone: Skill Enhancement Workshops for BPH, flexible ureteroscopy and PCNL; and in-booth presentations with world-renowned urologists featuring the MOSES Technology.

“We are excited to enhance and expand the value of the MOSES Technology for healthcare providers and patients by demonstrating meaningful clinical advantages in BPH procedures,” said Tzipi Ozer-Armon, CEO of Lumenis. “Together with our partners in the professional community, we are committed to continuously researching and furthering the benefits of this breakthrough technology and improving the standard of care in urology.”

Source: Company Press Release.